Publication:
Effectiveness of Modified Vaccinia Ankara-Bavaria Nordic Vaccination in a Population at High Risk of Mpox: A Spanish Cohort Study

Simple item page
dc.contributor.authorFontán-Vela, Mario
dc.contributor.authorHernando Sebastian, Victoria
dc.contributor.authorOlmedo, Carmen
dc.contributor.authorComa, Ermengol
dc.contributor.authorMartínez, Montse
dc.contributor.authorMoreno-Perez, David
dc.contributor.authorLorusso, Nicola
dc.contributor.authorVázquez Torres, María
dc.contributor.authorBarbas del Buey, José Francisco
dc.contributor.authorRoig-Sena, Javier
dc.contributor.authorPastor, Eliseo
dc.contributor.authorGalmés Truyols, Antònia
dc.contributor.authorArtigues Serra, Francisca
dc.contributor.authorSancho Martínez, Rosa María
dc.contributor.authorLatasa Zamalloa, Pello
dc.contributor.authorPérez Martínez, Olaia
dc.contributor.authorVázquez Estepa, Ana
dc.contributor.authorGarcía Rojas, Amós José
dc.contributor.authorBarreno Estévez, Ana Isabel
dc.contributor.authorSánchez-Migallón Naranjo, Alonso
dc.contributor.authorPérez Martín, Jaime Jesús
dc.contributor.authorPeces Jiménez, Pilar
dc.contributor.authorMorales Romero, Raquel
dc.contributor.authorCastilla, Jesús
dc.contributor.authorGarcía Cenoz, Manuel
dc.contributor.authorHuerta Huerta, Marta
dc.contributor.authorBoone, An Lieve Dirk
dc.contributor.authorMacías Ortiz, María José
dc.contributor.authorÁlvarez Río, Virginia
dc.contributor.authorRodríguez Recio, María Jesús
dc.contributor.authorMerino Díaz, María
dc.contributor.authorBerradre Sáenz, Belén
dc.contributor.authorVillegas-Moreno, María Teresa
dc.contributor.authorLimia, Aurora
dc.contributor.authorDiaz Franco, Asuncion
dc.contributor.authorMonge Corella, Susana
dc.contributor.authorSpanish MPOX vaccine effectiveness study group
dc.contributor.authorJarrin-Vera, Inmaculada
dc.date.accessioned2023-12-18T18:10:01Z
dc.date.available2023-12-18T18:10:01Z
dc.date.issued2024
dc.description.abstractBackground: With over 7,500 cases notified since April 2022, Spain has experienced the highest incidence of mpox in Europe. From July 12th onwards, the Modified Vaccinia Ankara-Bavaria Nordic (MVA-BN) smallpox vaccine was offered as pre-exposure prophylaxis for individuals at high-risk of mpox, including those receiving pre-exposure prophylaxis for HIV (HIV-PrEP). Our aim was to assess the effectiveness of one dose of MVA-BN vaccine as pre-exposure against mpox virus (MPXV) infection in persons on HIV-PrEP. Methods: We conducted a national retrospective cohort study between July 12 and December 12, 2022. Individuals ≥18 years, receiving HIV-PrEP as of July 12 and with no previous MPXV infection or vaccination were eligible. Each day, we matched individuals receiving a first dose of MVA-BN vaccine and unvaccinated controls of the same age group and region. We used a Kaplan-Meier estimator and calculate risk ratios (RR) and vaccine effectiveness (VE = 1-RR). Results: We included 5,660 matched pairs, with a median follow-up of 62 days (interquartile range 24-97). Mpox cumulative incidence was 5.6 per 1,000 (25 cases) in unvaccinated and 3.5 per 1,000 (18 cases) in vaccinated. No effect was found during days 0-6 post-vaccination (VE -38.3; 95% confidence interval (95%CI): -332.7; 46.4), but VE was 65% in ≥7 days (95%CI 22.9; 88.0) and 79% in ≥14 days (95%CI 33.3; 100.0) post-vaccination. Conclusions: One dose of MVA-BN vaccine offered protection against mpox in a most-at-risk population shortly after the vaccination. Further studies need to assess the VE of a second dose and the duration of protection over time.es_ES
dc.description.peerreviewedSíes_ES
dc.format.number2
dc.format.page476-483es_ES
dc.format.volume78
dc.identifier.citationClin Infect Dis. 2024 Feb 17;78(2):476-483.es_ES
dc.identifier.doi10.1093/cid/ciad645es_ES
dc.identifier.e-issn1537-6591es_ES
dc.identifier.issn1058-4838es_ES
dc.identifier.journalClinical Infectious Diseaseses_ES
dc.identifier.pubmedID37864849es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/16837
dc.language.isoenges_ES
dc.publisherOxford University Presses_ES
dc.relation.publisherversionhttps://doi.org/10.1093/cid/ciad645es_ES
dc.repisalud.centroISCIII::Centro Nacional de Epidemiologíaes_ES
dc.repisalud.institucionISCIIIes_ES
dc.rights.accessRightsopen accesses_ES
dc.rights.licenseAtribución 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectmpoxes_ES
dc.subjectMonkeypoxes_ES
dc.subjectVaccine effectivenesses_ES
dc.subjectMVA-BN vaccinees_ES
dc.subjectPre-exposure prophylaxis
dc.titleEffectiveness of Modified Vaccinia Ankara-Bavaria Nordic Vaccination in a Population at High Risk of Mpox: A Spanish Cohort Studyes_ES
dc.typeresearch articlees_ES
dc.type.hasVersionVoRes_ES
dspace.entity.typePublication
relation.isAuthorOfPublicationacb2d83b-fdee-49ed-8169-8b093c906160
relation.isAuthorOfPublication2a997c3a-ac1c-404f-8443-a2c79a5ebcd5
relation.isAuthorOfPublication7ac13a7f-3d30-4846-8b51-b7505c7df45c
relation.isAuthorOfPublication8539fce0-7a71-478e-8fb6-d5573d1763c2
relation.isAuthorOfPublication98ad881c-e9ea-43a8-ae35-fa4d295b628d
relation.isAuthorOfPublicationa0bb4f4f-11f0-487e-bf93-0b13f90057cc
relation.isAuthorOfPublication.latestForDiscoveryacb2d83b-fdee-49ed-8169-8b093c906160
Files
Original bundle
Now showing 1 - 2 of 2
Thumbnail Image
Name:
EffectivenessModifiedVacciniaAnkara-BavariaNordic_2024.pdf
Size:
514.77 KB
Format:
Adobe Portable Document Format
Description:
Articulo
Download
Thumbnail Image
Name:
Supplementary_EffectivenessMVA-BN_Vaccination_2023.pdf
Size:
823.2 KB
Format:
Adobe Portable Document Format
Description:
supplementary material
Download
Collections
Centro Nacional de Epidemiología (CNE)
IdiSNA - Instituto de Investigación Sanitaria de Navarra (Navarra)